Computational precision medicine company, Genialis, has announced it has raised more than $13M in Series A financing.
Genialis uses machine learning and high-throughput omics data to understand underlying disease biology and predict patients' response to targeted therapies. The company plans to use the funding to expand its proprietary platform ResponderID and to build out its collection of clinically validated biomarker models in order to transform diagnosis for cancer patients. So far, ResponderID has been used in collaboration with biopharma to analyse clinical trials data and to inform future trial design.
“ResponderID, Genialis’ predictive biomarker platform, enables precision medicine by identifying patients that are most likely to respond to treatments. Its use in drug development will optimize study designs and improve chances of clinical trials success, driving much-needed productivity gains for pharma R&D and accelerating the time to market for promising new drugs,” said Hamzeh Abdul-Hadi, Investment Director at Debiopharm Innovation Fund.
Click here to read the original news story.